Scinai Immunotherapeutics Ltd.(SCNI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

SCNI Scinai Immunotherapeutics Ltd.

Pre-Mkt 08-14 08:11:45 EDT

0.2400

-0.0070

-2.83%

盘前0.2400

+0.00000.00%

07:42 EDT

High0.2500	Low0.2308	Vol64.82K
Open0.2450	D1 Closing0.2470	Amplitude7.77%
Mkt Cap1.24M	Tradable Cap1.05M	Total Shares5.17M
T/O15.58K	T/O Rate1.49%	Tradable Shares4.36M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"SCNI","market":"US","secType":"STK","nameCN":"Scinai Immunotherapeutics Ltd.","latestPrice":0.24,"timestamp":1786651200000,"preClose":0.247,"halted":0,"volume":64817,"hourTrading":{"tag":"盘前","latestPrice":0.24,"preClose":0.24,"latestTime":"07:42 EDT","volume":1434,"amount":344.14598982,"timestamp":1786707753821,"change":0,"changeRate":0,"amplitude":0.058333},"delay":0,"changeRate":-0.028340080971659944,"floatShares":4356400,"shares":5169400,"eps":-1.133579,"marketStatus":"Pre-Mkt","change":-0.007,"latestTime":"08-14 08:11:45 EDT","open":0.245,"high":0.25,"low":0.2308,"amount":15578.51510821,"amplitude":0.077733,"askPrice":0.2499,"askSize":300,"bidPrice":0.24,"bidSize":56,"shortable":3,"etf":0,"ttmEps":-1.133579,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1786714200000},"marketStatusCode":1,"adr":0,"adrRate":4000,"listingDate":1431403200000,"exchange":"NASDAQ","adjPreClose":0.24,"preHourTrading":{"tag":"盘前","latestPrice":0.24,"preClose":0.24,"latestTime":"07:42 EDT","volume":1434,"amount":344.14598982,"timestamp":1786707753821,"change":0,"changeRate":0,"amplitude":0.058333},"postHourTrading":{"tag":"盘后","latestPrice":0.2415,"preClose":0.24,"latestTime":"18:06 EDT","volume":534,"amount":128.5226,"timestamp":1786658768548,"change":0.0015,"changeRate":0.00625,"amplitude":0.00625},"volumeRatio":0.34076224510587927},"requestUrl":"/m/hq/s/SCNI","defaultTab":"news","newsList":[{"id":"2658036987","title":"Press Release: Scinai Strengthens CDMO Leadership with Appointment of Eran Kuratz as Head of Supply Chain and Business Process Administration","url":"https://stock-news.laohu8.com/highlight/detail?id=2658036987","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658036987?lang=en_us&edition=fundamental","pubTime":"2026-08-10 18:35","pubTimestamp":1786358100,"startTime":"0","endTime":"0","summary":"Appointment strengthens operational infrastructure and supports integration and scale-up of Scinai's expanded CDMO platform.JERUSALEM, Aug. 10, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NAS","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EES","CDMO","BK4007","SCNI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642423069","title":"Scinai Q1 FY26 returns to profit at USD 3.58 million; revenue falls to USD 489,000","url":"https://stock-news.laohu8.com/highlight/detail?id=2642423069","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642423069?lang=en_us&edition=fundamental","pubTime":"2026-06-10 19:55","pubTimestamp":1781092536,"startTime":"0","endTime":"0","summary":"Scinai Immunotherapeutics posts Q1 2026 net income of USD 3.58 million, swinging from a year-earlier net loss due to a USD 6.16 million bargain purchase gain.Revenue falls to USD 489,000 from the prior-year quarter, including about USD 200,000 from the newly acquired Yavne facility.Operating loss widens to USD 2.47 million as cost of revenues rises to USD 1.61 million following the Recipharm Israel acquisition.Cash, cash equivalents and restricted cash climbs to USD 3.11 million at March 31 from USD 1.81 million at Dec. 31.Completed Recipharm Israel deal, added a second site in Yavne, consolidated CDMO operations under Scinai Biopharma Services, prioritized a systemic IL-17 bispecific NanoAb program.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260610:nNDL6N2wjw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SCNI","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642054423","title":"Press Release: Scinai Reports First Quarter 2026 Financial Results and Provides Corporate Update Highlighting Expansion of CDMO Platform and Advancement of Strategic Growth Initiatives","url":"https://stock-news.laohu8.com/highlight/detail?id=2642054423","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642054423?lang=en_us&edition=fundamental","pubTime":"2026-06-10 19:55","pubTimestamp":1781092500,"startTime":"0","endTime":"0","summary":"JERUSALEM, June 10, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. , , a biopharmaceutical company combining innovative therapeutic development with a revenue-generating CDMO subsidiary, today reported financial results for the three months ended March 31, 2026 and provided a corporate update.-- Completed the acquisition of Recipharm Israel, expanding the Company's. CDMO platform through the addition of a second manufacturing site in. Yavne, Israel, and establishing a strategic commercial collaboration with. -- Advanced multiple non-dilutive funding initiatives supporting the. lead validation program for the Company's NanoAb platform.\"The first quarter of 2026 marked an important milestone in Scinai's evolution. Through the acquisition of Recipharm Israel and the subsequent consolidation of our CDMO activities under Scinai Biopharma Services, we have expanded our operational footprint, manufacturing capabilities and commercial reach.Scinai today consists of two complementary busin","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SCNI","BK4139","BK4007","CDMO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636495568","title":"Scinai names Eilon Elmalem site head of Yavne CDMO facility","url":"https://stock-news.laohu8.com/highlight/detail?id=2636495568","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636495568?lang=en_us&edition=fundamental","pubTime":"2026-05-20 19:02","pubTimestamp":1779274946,"startTime":"0","endTime":"0","summary":"Scinai Immunotherapeutics appointed Eilon Elmalem as site head of its Yavne CDMO facility, effective June 14, 2026.Elmalem worked with Scinai for the past two years as an external consultant supporting CDMO operations and the Yavne facility’s transition planning; he will run site operations while continuing to oversee engineering.He has more than 20 years of experience in engineering and operations in biotech and pharma, including senior leadership roles at Merck and Sigma-Aldrich Millipore, where he served as VP of Engineering and Process Development.The knowledge-transfer process began May 10, 2026 under current site head Sylvia Kachalsky, who is expected to begin retirement leave ahead of her planned retirement later in 2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260520:nNDL6LWp5z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BLSP4452.SGD","LU2361045086.USD","LU0965508806.USD","LU0006306889.USD","LU1923622614.USD","LU0980610538.SGD","SG9999001176.SGD","LU1917777945.USD","BK4550","LU1116320737.USD","LU1430594728.SGD","LU1934455194.USD","SG9999014567.USD","BK4533","SG9999013999.USD","LU2361044949.HKD","LU2361044865.SGD","IE00BSNM7G36.USD","LU1066051225.USD","BK4007","SG9999015341.SGD","LU1291159041.SGD","LU1974910355.USD","LU0058720904.USD","LU0320765646.SGD","LU1941712348.USD","LU2023250504.SGD","LU2491050154.USD","BK4585","LU0861579265.USD","LU1061106388.HKD","LU2324357040.USD","LU0130517989.USD","LU2106854487.HKD","LU0432979614.USD","SG9999015358.SGD","LU1066053197.SGD","LU1116320901.HKD","SG9999014575.USD","LU2125909247.SGD","BK4559","BK4588","LU2491049909.HKD","LU0965509283.SGD","IE00BBT3K403.USD","SG9999002224.SGD","SGXZ57979304.SGD","SCNI","BK4534","LU0203345920.USD","SG9999001176.USD","LU2112291526.USD","LU1571399168.USD","SG9999001440.SGD","LU0985320562.USD","LU1069347547.HKD","LU1699723380.USD","LU2360032135.SGD","LU0868494708.USD","SG9999014559.SGD","LU1941712264.USD","LU1037948897.HKD","LU2125154778.USD","IE00BLSP4239.USD","LU1934455863.HKD","LU1989772840.SGD","IE00B4R5TH58.HKD","LU1201861249.SGD","LU0265550359.USD","LU0320765489.SGD","LU0265550946.USD","LU0965509010.AUD","LU0234572021.USD","LU2491050071.SGD","LU1929549753.HKD","LU0098860793.USD","LU0211331839.USD","LU2089984988.USD","IE00BN8TJ469.HKD","LU0208291251.USD","IE000M9KFDE8.USD","IE00BJT1NW94.SGD","LU1035773651.USD","LU0070302665.USD","BK4516","LU0122379950.USD","LU1989772923.USD","LU0106261372.USD","LU2023250843.SGD","LU1585245621.USD","LU2125909593.SGD","LU0289739699.SGD","IE00BFTCPJ56.SGD","SG9999002232.USD","LU0942090050.USD","IE0002141913.USD","IE00B2B36J28.USD","LU1037948541.HKD","LU0238689110.USD","LU1057294990.SGD","LU1023059063.AUD","LU1066051811.HKD","LU1989771016.USD","LU2433249047.HKD","LU1983299246.USD","LU0859254822.USD","LU0648001328.SGD","IE00BJJMRZ35.SGD","LU1162221912.USD","LU0266013472.USD","LU1093756168.USD","LU2125154935.USD","LU2357627491.SGD","SG9999014542.SGD","LU0965509101.SGD","IE00B1BXHZ80.USD","LU1093756325.SGD","LU0130102774.USD","LU0477156953.USD","LU2468319806.SGD","LU0868494617.USD","LU2461242641.AUD","IE0009355771.USD","LU1066051498.USD","LU1934455277.USD","LU0203347892.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636284964","title":"Press Release: Scinai Biopharma Services Appoints Eilon Elmalem as Site Head of Yavne CDMO Facility","url":"https://stock-news.laohu8.com/highlight/detail?id=2636284964","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636284964?lang=en_us&edition=fundamental","pubTime":"2026-05-20 19:00","pubTimestamp":1779274800,"startTime":"0","endTime":"0","summary":"JERUSALEM, May 20, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. , , a biopharmaceutical company advancing a pipeline of innovative inflammation and immunology therapeutics, today announced that its wholly owned subsidiary, Scinai Biopharma Services Ltd., a contract development and manufacturing organization , has appointed Mr. Eilon Elmalem as Site Head of its Yavne CDMO facility, effective June 14, 2026.Mr. Elmalem has worked with Scinai over the past two years as an external consultant and has supported the Company's CDMO activities and operational development efforts. More recently, he has been involved in the transition and operational integration planning of the Yavne facility. In his new role, Mr. Elmalem will assume responsibility for site operations while continuing to oversee engineering activities, supporting the continued growth and operational development of Scinai's CDMO platform.Mr. Reichman added: \"I would also like to thank Sylvia for her leadership of the Yavne ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SCNI","CDMO","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630634827","title":"ADRs Advance; Scinai Immunotherapeutics Ltd. Climbs 62%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630634827","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630634827?lang=en_us&edition=fundamental","pubTime":"2026-04-25 04:30","pubTimestamp":1777062600,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.International stocks trading in New York closed higher on Friday, as the S&P/BNY Mellon index of American depositary receipts increased 1.6% to 258.27.The European index gained 0.8% to 225.38. The Asian index rose 2.6% to 344.32. The Latin American index dropped 0.1% to 295.25, while the emerging-markets index added 3.2% to 602.34.Israel's Scinai Immunotherapeutics Ltd. was the biggest leader during the session, soaring 62% to 74 cents, and United Kingdom-based Wing Yip Food Holdings Group Ltd. rocketed 24% to 65 cents. BingEx Ltd., which is based in China, rounded out the top three leaders on Friday, with shares jumping 18% to $3.16.XIAO-I Corp., based in China, posted the largest decline, plummeting 30% to 76 cents, followed by shares of China's CNFinance Holdings Ltd., which plunged 17% to $2.85. Shares of China-based 17 Education & Technology Group Inc. tumbled 14% to $2.23.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","SCNI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629169842","title":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 09:37 AM","url":"https://stock-news.laohu8.com/highlight/detail?id=2629169842","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629169842?lang=en_us&edition=fundamental","pubTime":"2026-04-24 21:37","pubTimestamp":1777037853,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 09:37 AM","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260424:nAQN2LW0J2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SCNI","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629841741","title":"Why Is Scinai Immunotherapeutics Stock (SCNI) Up Today?","url":"https://stock-news.laohu8.com/highlight/detail?id=2629841741","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629841741?lang=en_us&edition=fundamental","pubTime":"2026-04-24 20:50","pubTimestamp":1777035047,"startTime":"0","endTime":"0","summary":"Scinai Immunotherapeutics stock was on the rise after the company announced a $2.61 million private placement.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/why-is-scinai-immunotherapeutics-stock-scni-up-today?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/why-is-scinai-immunotherapeutics-stock-scni-up-today?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4007","SCNI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629984997","title":"Scinai Immunotherapeutics announces $2.61M private placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2629984997","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629984997?lang=en_us&edition=fundamental","pubTime":"2026-04-24 20:16","pubTimestamp":1777033015,"startTime":"0","endTime":"0","summary":"Scinai Immunotherapeutics (SCNI) announced that it has entered into a securities purchase agreement with an institutional life sciences investor, a...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/scinai-immunotherapeutics-announces-2-61m-private-placement-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/scinai-immunotherapeutics-announces-2-61m-private-placement-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SCNI","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629084610","title":"Press Release: Scinai Immunotherapeutics Announces $2.61 Million Private Placement Financing","url":"https://stock-news.laohu8.com/highlight/detail?id=2629084610","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629084610?lang=en_us&edition=fundamental","pubTime":"2026-04-24 20:00","pubTimestamp":1777032000,"startTime":"0","endTime":"0","summary":"-- Financing led by institutional life sciences investor, with participation. In addition, the Company entered into a warrant inducement agreement with an existing institutional investor of the Company for the immediate exercise of warrants to purchase up to 229,310 ADSs of its ordinary shares  at an exercise price of $0.48 per ADS.The aggregate gross proceeds from the private placement and the warrant inducement transaction are approximately $2.61 million, before deducting fees and expenses, and the closing of the transactions is expected to occur on or about April 27, 2026, subject to satisfaction of customary closing conditions.A.G.P./Alliance Global Partners acted as the sole financial advisor for the transactions.The offer and sale of the foregoing securities will be made in reliance on an exemption from registration under Section 4 of the Securities Act of 1933, as amended , and Regulation D promulgated thereunder. Accordingly, the securities issued in the private placement may n","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","CDMO","SCNI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625676952","title":"Scinai Immunotherapeutics completes strategic reorganization","url":"https://stock-news.laohu8.com/highlight/detail?id=2625676952","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625676952?lang=en_us&edition=fundamental","pubTime":"2026-04-06 19:17","pubTimestamp":1775474243,"startTime":"0","endTime":"0","summary":"Scinai Immunotherapeutics (SCNI) announced the completion of a strategic corporate reorganization establishing a dedicated CDMO platform alongside ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/scinai-immunotherapeutics-completes-strategic-reorganization-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/scinai-immunotherapeutics-completes-strategic-reorganization-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","SCNI","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624915513","title":"Scinai Immunotherapeutics FY EPS $(3.56), Sales $1.311M Up From $658.000K YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2624915513","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624915513?lang=en_us&edition=fundamental","pubTime":"2026-04-01 20:09","pubTimestamp":1775045397,"startTime":"0","endTime":"0","summary":"Scinai Immunotherapeutics (NASDAQ:SCNI) reported quarterly losses of $(3.56) per share.  The company reported $1.311 million in sales this quarter. This is a 99.24 percent increase over sales of $658.000 thousand the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/04/51595491/scinai-immunotherapeutics-fy-eps-3-56-sales-1-311m-up-from-658-000k-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SCNI","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620240439","title":"Scinai Immunotherapeutics highlights expanded CDMO platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2620240439","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620240439?lang=en_us&edition=fundamental","pubTime":"2026-03-19 20:08","pubTimestamp":1773922085,"startTime":"0","endTime":"0","summary":"Scinai Immunotherapeutics (SCNI) announced its participation in BIO-Europe Spring 2026, taking place March 23-25 in Lisbon, Portugal. During the co...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/scinai-immunotherapeutics-highlights-expanded-cdmo-platform-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/scinai-immunotherapeutics-highlights-expanded-cdmo-platform-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4007","CDMO","SCNI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616353664","title":"Press Release: Scinai Signs Second Amendment to PinCell Option Agreement and Submits Revised EUR12 Million Non-Dilutive FENG Application to Advance PC111 Through Human Proof of Concept","url":"https://stock-news.laohu8.com/highlight/detail?id=2616353664","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616353664?lang=en_us&edition=fundamental","pubTime":"2026-03-02 22:20","pubTimestamp":1772461200,"startTime":"0","endTime":"0","summary":"JERUSALEM, March 2, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. ;, today announced the execution of a Second Amendment to its Binding Option Agreement for the acquisition of PinCell S.r.l., and the submission of a revised application under the European Funds for the Modern Economy  SMART Path program.The Company's revised application seeks EUR12 million in non-dilutive, non-repayable funding to support a EUR15 million integrated R&D program for PC111 a fully human monoclonal antibody targeting soluble Fas Ligand  for the treatment of pemphigus vulgaris  and Stevens--Johnson Syndrome/Toxic Epidermal Necrolysis , representing 80% project co-financing. The Company expects a funding decision within approximately three to four months following submission.The Second Amendment aligns the option timeline with the grant evaluation process. Under the amended terms, the deadline for fulfillment of the option conditions extends to August 31, 2026, and the option exercise period extends to ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4077","BK4139","BK4007","CDMO","FENG","SCNI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614272346","title":"ADRs Advance; Scinai Immunotherapeutics Ltd. Climbs 18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614272346","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614272346?lang=en_us&edition=fundamental","pubTime":"2026-02-25 05:30","pubTimestamp":1771968600,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.International stocks trading in New York closed higher on Tuesday, as the S&P/BNY Mellon index of American depositary receipts gained 1.0% to 265.26.The European index rose 0.3% to 230.14. The Asian index increased 1.8% to 356.82. The Latin American index increased 1.5% to 290.03, while the emerging-markets index gained 2.5% to 606.46.Israel's Scinai Immunotherapeutics Ltd. was the biggest leader during the session, jumping 18% to 86 cents, and China-based The9 Ltd. surged 17% to $5.92. Canaan Inc., which is based in China, rounded out the top three leaders on Tuesday, with shares surging 16% to 50 cents.Yimutian Inc., based in China, posted the largest decline, plummeting 28% to 63 cents, followed by shares of China's Huize Holding Ltd., which plunged 11% to $1.84. Shares of China-based DouYu International Holdings Ltd. tumbled 11% to $4.48.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","SCNI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612519064","title":"Press Release: Scinai Announces Completion of Acquisition of Recipharm Israel Ltd. and Strategic Commercial Collaboration with Recipharm","url":"https://stock-news.laohu8.com/highlight/detail?id=2612519064","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612519064?lang=en_us&edition=fundamental","pubTime":"2026-02-17 20:00","pubTimestamp":1771329600,"startTime":"0","endTime":"0","summary":"JERUSALEM, Feb. 17, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd.  , a biopharmaceutical company developing inflammation and immunology (I&I) therapeutics and operating a growing CDMO business, today announced that it has acquired 100% of the shares of Recipharm Israel Ltd., which operates Recipharm's site in Yavne, Israel, and entered into a long-term strategic commercial collaboration with Recipharm.The transactions significantly expand Scinai's manufacturing footprint, capabilities, and commercial positioning, strengthening its CDMO platform and creating a differentiated, end-to-end development and manufacturing offering spanning early development directly by Scinai and late-stage clinical and commercial supply by Recipharm. Under the collaboration agreement, development activities and tech transfer will be set up between the companies in a manner designed to facilitate an efficient and frictionless graduation of Scinai clients to Recipharm at the appropriate stage. As a resul","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CDMO","BK4007","91348","SCNI"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.scinai.com","stockEarnings":[{"period":"1week","weight":-0.0726},{"period":"1month","weight":-0.0054},{"period":"3month","weight":-0.5524},{"period":"6month","weight":-0.6776},{"period":"1year","weight":-0.8571},{"period":"ytd","weight":-0.663}],"compareEarnings":[{"period":"1week","weight":0.0121},{"period":"1month","weight":0.0346},{"period":"3month","weight":0.0524},{"period":"6month","weight":0.141},{"period":"1year","weight":0.2062},{"period":"ytd","weight":0.1407}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was incorporated in 2003 and is headquartered in Jerusalem, Israel.","yearOnYearQuotes":[{"month":1,"riseRate":0.636364,"avgChangeRate":0.123027},{"month":2,"riseRate":0.272727,"avgChangeRate":-0.04681},{"month":3,"riseRate":0.272727,"avgChangeRate":-0.045692},{"month":4,"riseRate":0.545455,"avgChangeRate":0.095382},{"month":5,"riseRate":0.454545,"avgChangeRate":-0.012574},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.074782},{"month":7,"riseRate":0.583333,"avgChangeRate":0.068828},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.05296},{"month":9,"riseRate":0.272727,"avgChangeRate":-0.108328},{"month":10,"riseRate":0.545455,"avgChangeRate":-0.094214},{"month":11,"riseRate":0.454545,"avgChangeRate":-0.010725},{"month":12,"riseRate":0.272727,"avgChangeRate":-0.063466}],"exchange":"NASDAQ","name":"Scinai Immunotherapeutics Ltd.","nameEN":"Scinai Immunotherapeutics Ltd.","securityTypeName":"DR","adrRate":"1:4000"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Scinai Immunotherapeutics Ltd.(SCNI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Scinai Immunotherapeutics Ltd.(SCNI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Scinai Immunotherapeutics Ltd.,SCNI,Scinai Immunotherapeutics Ltd.股票,Scinai Immunotherapeutics Ltd.股票老虎,Scinai Immunotherapeutics Ltd.股票老虎国际,Scinai Immunotherapeutics Ltd.行情,Scinai Immunotherapeutics Ltd.股票行情,Scinai Immunotherapeutics Ltd.股价,Scinai Immunotherapeutics Ltd.股市,Scinai Immunotherapeutics Ltd.股票价格,Scinai Immunotherapeutics Ltd.股票交易,Scinai Immunotherapeutics Ltd.股票购买,Scinai Immunotherapeutics Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Scinai Immunotherapeutics Ltd.(SCNI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Scinai Immunotherapeutics Ltd.(SCNI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}